Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 66, Number 1, January 10, 2006
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gurol, M. E.
Right arrow Articles by Greenberg, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gurol, M. E.
Right arrow Articles by Greenberg, S. M.
Related Collections
Right arrowRelated Articles
NEUROLOGY 2006;66:23-29
© 2006 American Academy of Neurology

Plasma ß-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy

M. E. Gurol, MD, M. C. Irizarry, MD, E. E. Smith, MD, S. Raju, PhD, R. Diaz-Arrastia, MD, PhD, T. Bottiglieri, PhD, J. Rosand, MD, MSc, J. H. Growdon, MD and S. M. Greenberg, MD, PhD

From Clinical Trials Unit and Memory Disorders Unit (M.E.G., M.C.I., E.E.S., S.R., J.R., J.H.G., S.M.G.), Department of Neurology, Massachusetts General Hospital, Boston; Department of Neurology (R.D.-A.), University of Texas Southwestern Medical Center, Dallas; and Baylor Institute of Metabolic Disease (T.B.), Dallas, TX.

Address correspondence and reprint requests to Dr. Steven M. Greenberg, Wang ACC 836, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114; e-mail: sgreenberg{at}partners.org

Background: Microvascular brain injury, typically measured by extent of white matter hyperintensity (WMH) on MRI, is an important contributor to cognitive impairment in the elderly. Recent studies suggest a role for circulating ß-amyloid peptide in microvascular dysfunction and white matter disease.

Methods: The authors performed a cross-sectional study of clinical, biochemical, and genetic factors associated with WMH in 54 subjects with Alzheimer disease (AD) or mild cognitive impairment (AD/MCI) and an independent group of 42 subjects with cerebral amyloid angiopathy (CAA). Extent of WMH was determined by computer-assisted volumetric measurement normalized to intracranial size (nWMH). Biochemical measurements included plasma concentrations of the 40- and 42-amino acid species of ß-amyloid (Aß40 and Aß42) detected by specific enzyme-linked immunosorbent assays.

Results: Plasma Aß40 concentrations were associated with nWMH in both groups (correlation coefficient = 0.48 in AD/MCI, 0.42 in CAA, p ≤ 0.005). Plasma Aß40 remained independently associated with nWMH after adjustment for potential confounders among age, hypertension, diabetes, homocysteine, creatinine, folate, vitamin B12, and APOE genotype. The presence of lacunar infarctions was also associated with increased Aß40 in both groups. nWMH was greater in CAA (19.8 cm3) than AD (11.1 cm3) or MCI (10.0 cm3; p < 0.05 for both comparisons).

Conclusions: Plasma ß-amyloid 40 concentration is independently associated with extent of white matter hyperintensity in subjects with Alzheimer disease, mild cognitive impairment, or cerebral amyloid angiopathy. If confirmed in longitudinal studies, these data would suggest circulating ß-amyloid peptide as a novel biomarker or risk factor for microvascular damage in these common diseases of the elderly.

Editorial, see page 6

Supported by the NIH (R01 NS04140, T32 NS048005, and P50 AG05134) and the Lawrence J. and Anne Cable Rubenstein Foundation.

Disclosure: The authors report no conflicts of interest.

Received June 20, 2005. Accepted in final form September 19, 2005.


Related Articles

January 10 Highlights
Neurology 2006 66: 2-3. [Full Text] [PDF]

Does the white matter matter in Alzheimer disease and cerebral amyloid angiopathy?
Jin-Moo Lee and Hugh S. Markus
Neurology 2006 66: 6-7. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Clin. Chem.Home page
R. Obeid, A. Schadt, U. Dillmann, P. Kostopoulos, K. Fassbender, and W. Herrmann
Methylation Status and Neurodegenerative Markers in Parkinson Disease
Clin. Chem., October 1, 2009; 55(10): 1852 - 1860.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
O. Godin, C. Tzourio, P. Maillard, A. Alperovitch, B. Mazoyer, and C. Dufouil
Apolipoprotein E Genotype Is Related to Progression of White Matter Lesion Load
Stroke, October 1, 2009; 40(10): 3186 - 3190.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
M. Gomis, T. Sobrino, A. Ois, M. Millan, A. Rodriguez-Campello, N. P. de la Ossa, R. Rodriguez-Gonzalez, J. Jimenez-Conde, E. Cuadrado-Godia, J. Roquer, et al.
Plasma {beta}-Amyloid 1-40 Is Associated With the Diffuse Small Vessel Disease Subtype
Stroke, October 1, 2009; 40(10): 3197 - 3201.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
L. Paternoster, W. Chen, and C. L.M. Sudlow
Genetic Determinants of White Matter Hyperintensities on Brain Scans: A Systematic Assessment of 19 Candidate Gene Polymorphisms in 46 Studies in 19 000 Subjects * Supplemental References
Stroke, June 1, 2009; 40(6): 2020 - 2026.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
E. M. Arsava, R. Rahman, J. Rosand, J. Lu, E. E. Smith, N. S. Rost, A. B. Singhal, M. H. Lev, K. L. Furie, W. J. Koroshetz, et al.
Severity of leukoaraiosis correlates with clinical outcome after ischemic stroke
Neurology, April 21, 2009; 72(16): 1403 - 1410.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
W. T. Kimberly, A. Gilson, N. S. Rost, J. Rosand, A. Viswanathan, E. E. Smith, and S. M. Greenberg
Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy
Neurology, April 7, 2009; 72(14): 1230 - 1235.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
A. Viswanathan
High-Dose B Vitamin Supplementation as a Disease-Modifying Therapy in Alzheimer Disease
Arch Neurol, April 1, 2009; 66(4): 520 - 522.
[Full Text] [PDF]

Home page
 NeurologyHome page
A. Viswanathan, S. Raj, S. M. Greenberg, M. Stampfer, S. Campbell, B. T. Hyman, and M. C. Irizarry
Plasma A{beta}, homocysteine, and cognition: The Vitamin Intervention for Stroke Prevention (VISP) trial
Neurology, January 20, 2009; 72(3): 268 - 272.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
E. E. Smith, M. Vijayappa, F. Lima, P. Delgado, L. Wendell, J. Rosand, and S. M. Greenberg
Impaired visual evoked flow velocity response in cerebral amyloid angiopathy
Neurology, October 28, 2008; 71(18): 1424 - 1430.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
A. M. Brickman, L. S. Honig, N. Scarmeas, O. Tatarina, L. Sanders, M. S. Albert, J. Brandt, D. Blacker, and Y. Stern
Measuring Cerebral Atrophy and White Matter Hyperintensity Burden to Predict the Rate of Cognitive Decline in Alzheimer Disease
Arch Neurol, September 1, 2008; 65(9): 1202 - 1208.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
A. Viswanathan, P. Patel, R. Rahman, R. N. K. Nandigam, C. Kinnecom, L. Bracoud, J. Rosand, H. Chabriat, S. M. Greenberg, and E. E. Smith
Tissue Microstructural Changes Are Independently Associated With Cognitive Impairment in Cerebral Amyloid Angiopathy
Stroke, July 1, 2008; 39(7): 1988 - 1992.
[Abstract] [Full Text] [PDF]

Home page
 AM J ALZHEIMERS DIS OTHER DEMENHome page
P. J. Modrego, I. Monleon, and M. Sarasa
The Clinical Significance of Plasmatic Amyloid A{beta}-40 Peptide Levels in Alzheimer's Disease Patients Treated With Galantamine
American Journal of Alzheimer's Disease and Other Dementias, June 1, 2008; 23(3): 286 - 290.
[Abstract] [PDF]

Home page
 NeurologyHome page
O. L. Lopez, L. H. Kuller, P. D. Mehta, J. T. Becker, H. M. Gach, R. A. Sweet, Y. F. Chang, R. Tracy, and S. T. DeKosky
Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study
Neurology, May 6, 2008; 70(19): 1664 - 1671.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
X. Sun, D. C. Steffens, R. Au, M. Folstein, P. Summergrad, J. Yee, I. Rosenberg, D. M. Mwamburi, and W. Q. Qiu
Amyloid-Associated Depression: A Prodromal Depression of Alzheimer Disease?
Arch Gen Psychiatry, May 1, 2008; 65(5): 542 - 550.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
H. Ay, E. M. Arsava, J. Rosand, K. L. Furie, A. B. Singhal, P. W. Schaefer, O. Wu, R. G. Gonzalez, W. J. Koroshetz, and A. G. Sorensen
Severity of Leukoaraiosis and Susceptibility to Infarct Growth in Acute Stroke
Stroke, May 1, 2008; 39(5): 1409 - 1413.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
C. M. Holland, E. E. Smith, I. Csapo, M. E. Gurol, D. A. Brylka, R. J. Killiany, D. Blacker, M. S. Albert, C. R.G. Guttmann, and S. M. Greenberg
Spatial Distribution of White-Matter Hyperintensities in Alzheimer Disease, Cerebral Amyloid Angiopathy, and Healthy Aging
Stroke, April 1, 2008; 39(4): 1127 - 1133.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
D. J. Libon, C. C. Price, T. Giovannetti, R. Swenson, B. M. Bettcher, K. M. Heilman, and A. Pennisi
Linking MRI Hyperintensities With Patterns of Neuropsychological Impairment: Evidence for a Threshold Effect
Stroke, March 1, 2008; 39(3): 806 - 813.
[Abstract] [Full Text] [PDF]

Home page
 PNHome page
M. O'Sullivan
Leukoaraiosis
Practical Neurology, January 1, 2008; 8(1): 26 - 38.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. Kinnecom, M. H. Lev, L. Wendell, E. E. Smith, J. Rosand, M. P. Frosch, and S. M. Greenberg
Course of cerebral amyloid angiopathy-related inflammation
Neurology, April 24, 2007; 68(17): 1411 - 1416.
[Abstract] [Full Text] [PDF]

Home page
 Age AgeingHome page
B. Thanvi and T. Robinson
Sporadic cerebral amyloid angiopathy--an important cause of cerebral haemorrhage in older people
Age Ageing, November 1, 2006; 35(6): 565 - 571.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
Y. W. Chen, M. E. Gurol, J. Rosand, A. Viswanathan, S. M. Rakich, T. R. Groover, S. M. Greenberg, and E. E. Smith
Progression of white matter lesions and hemorrhages in cerebral amyloid angiopathy.
Neurology, July 11, 2006; 67(1): 83 - 87.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
D. H. Salat, E. E. Smith, D. S. Tuch, T. Benner, V. Pappu, K. M. Schwab, M. E. Gurol, H. D. Rosas, J. Rosand, and S. M. Greenberg
White Matter Alterations in Cerebral Amyloid Angiopathy Measured by Diffusion Tensor Imaging
Stroke, July 1, 2006; 37(7): 1759 - 1764.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J.-M. Lee and H. S. Markus
Does the white matter matter in Alzheimer disease and cerebral amyloid angiopathy?
Neurology, January 10, 2006; 66(1): 6 - 7.
[Full Text] [PDF]